Chimerix's Tembexa (brincidofovir) Receives the US FDA's Approval for the Treatment of Smallpox
Shots:
- The approval is based on efficacy data in two lethal orthopoxvirus animal models- i.e rabbitpox model & mousepox model evaluating Tembexa (100 mg- PO- tablets & 10 mg/mL oral suspension dosed- given once weekly for 2 wks.) vs PBO in adult & pediatric patients with Smallpox
- The studies for each model showed that the therapy resulted in significant survival- following delayed treatment after animals were infected with a lethal viral dose.
- Tembexa is the First smallpox antiviral approved for all age groups- including infants- and patients who have difficulty in swallowing. The therapy is being developed under an ongoing collaboration with BARDA
Ref: Chimerix | Image: Chimerix
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com